C-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes: an individual participant meta-analysis

Effect of Verapamil on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 Diabetes

(2023) Gregory P. Forlenza et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Type 1 diabetes

(2023) Teresa Quattrin et al.   LANCET

Residual β cell function in long-term type 1 diabetes associates with reduced incidence of hypoglycemia

(2021) Rose A. Gubitosi-Klug et al.   JOURNAL OF CLINICAL INVESTIGATION

Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial

(2021) Matthias von Herrath et al.   Lancet Diabetes & Endocrinology

Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

(2021) Stephen E Gitelman et al.   Lancet Diabetes & Endocrinology

Immunotherapy for type 1 diabetes

(2021) L A Allen et al.   BRITISH MEDICAL BULLETIN

IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetes

(2021) Carla J. Greenbaum et al.   JCI Insight

HbA1c Levels in Type 1 Diabetes from Early Childhood to Older Adults: A Deeper Dive into the influence of technology and socio-economic status on HbA1c in the T1D Exchange Clinic Registry Findings.

(2020) Kellee M. Miller et al.   Diabetes Technology & Therapeutics

Randomized 52-week Phase 2 Trial of Albiglutide Versus Placebo in Adult Patients With Newly Diagnosed Type 1 Diabetes

(2020) Paolo Pozzilli et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Clinical Impact of Residual C-Peptide Secretion in Type 1 Diabetes on Glycemia and Microvascular Complications

(2020) Anita Jeyam et al.   DIABETES CARE

Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes

(2020) Teresa Quattrin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Human plasma‐derived alpha 1 ‐proteinase inhibitor in patients with new‐onset type 1 diabetes mellitus: A randomized, placebo‐controlled proof‐of‐concept study

(2020) William H. Lagarde et al.   PEDIATRIC DIABETES

Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA1cin New-Onset Type 1 Diabetes

(2018) Michael J. Haller et al.   DIABETES CARE

Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study

(2018) Araz Rawshani et al.   LANCET

Validation of the BETA-2 Score: An Improved Tool to Estimate Beta Cell Function After Clinical Islet Transplantation Using a Single Fasting Blood Sample

(2016) S. Forbes et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Glucose Concentrations of Less Than 3.0 mmol/L (54 mg/dL) Should Be Reported in Clinical Trials: A Joint Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes: Table 1

(2016)   DIABETES CARE

Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association

(2015) Richard A. Insel et al.   DIABETES CARE

Estimated Life Expectancy in a Scottish Cohort With Type 1 Diabetes, 2008-2010

(2015) Shona J. Livingstone et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Low-Dose Otelixizumab Anti-CD3 Monoclonal Antibody DEFEND-1 Study: Results of the Randomized Phase III Study in Recent-Onset Human Type 1 Diabetes

(2014) Ronnie Aronson et al.   DIABETES CARE

Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial: Metabolic and Immunologic Features at Baseline Identify a Subgroup of Responders

(2013) K. C. Herold et al.   DIABETES

Teplizumab Preserves C-Peptide in Recent-Onset Type 1 Diabetes: Two-Year Results From the Randomized, Placebo-Controlled Protege Trial

(2013) W. Hagopian et al.   DIABETES

The Effects of Inpatient Hybrid Closed-Loop Therapy Initiated Within 1 Week of Type 1 Diabetes DiagnosisDiabetes Research in Children Network (DirecNet) and Type 1 Diabetes TrialNet Study Groups

(2013)   Diabetes Technology & Therapeutics

The clinical utility of C-peptide measurement in the care of patients with diabetes

(2013) A. G. Jones et al.   DIABETIC MEDICINE

Efficacy and safety of low-dose otelixizumab anti-CD3 monoclonal antibody in preserving C-peptide secretion in adolescent type 1 diabetes: DEFEND-2, a randomized, placebo-controlled, double-blind, multi-centre study

(2013) P. Ambery et al.   DIABETIC MEDICINE

Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials

(2013) Antoinette Moran et al.   LANCET

Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial

(2013) Mark R Rigby et al.   Lancet Diabetes & Endocrinology

Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial

(2013) Stephen E Gitelman et al.   Lancet Diabetes & Endocrinology

SUITO Index for Evaluation of Clinical Islet Transplantation

(2012) Morihito Takita et al.   CELL TRANSPLANTATION

Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial

(2011) Diane K Wherrett et al.   LANCET

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial

(2011) Nicole Sherry et al.   LANCET

Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial

(2011) Tihamer Orban et al.   LANCET

Failure to Preserve  -Cell Function With Mycophenolate Mofetil and Daclizumab Combined Therapy in Patients With New- Onset Type 1 Diabetes

(2010) P. A. Gottlieb et al.   DIABETES CARE

New Definition for the Partial Remission Period in Children and Adolescents With Type 1 Diabetes

(2009) H. B. Mortensen et al.   DIABETES CARE

Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function

(2009) Mark D. Pescovitz et al.   NEW ENGLAND JOURNAL OF MEDICINE